Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combigan for Diabetic Macular Edema
NCT02718547Unknown
- Sponsor
- Meir Medical Center
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brimonidine in diabetic macular edema (DME), sponsored by Meir Medical Center. Primary endpoint: Change of at least 50 micron in Macular edema at 3 months. Status: unknown.
02
Drugs
brimonidine
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02718547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718547.